Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
The novel CDK4 inhibitor PF-07220060 in combination with endocrine therapy demonstrated a favorable safety profile and generated robust response rates in heavily pretreated patients with hormone receptor (HR)–positive, HER2-negative metastatic breast …